论文部分内容阅读
目的对骨肉瘤中人端粒酶逆转录酶(hTERT)的表达进行定性及定量检测,探讨hTERT在骨肉瘤中的表达及意义。方法用免疫细胞/组织化学法分别定性检测人宫颈癌细胞株HeLa、人骨肉瘤细胞株U2-OS、MG-63、SAOS-2及15例骨肉瘤组织中hTERT的表达情况;用蛋白印迹法(Western-blot,WB)定量检测上述细胞株及7例骨肉瘤组织中hTERT的表达情况。结果免疫细胞/组织化学显示,HeLa细胞hTERT表达率最高(95.16%);MG-63、SAOS-2、U2-OS细胞系中hTERT阳性率分别为8.75%、5.26%、2.33%;骨肉瘤组织中hTERT表达阳性率26.7%(4/15)。蛋白印迹法显示,Hela、MG-63及两个骨肉瘤样本(OS1和OS2)有hTERT表达,U2-OS及SAOS-2中几乎没有hTERT表达。结论 hTERT在骨肉瘤中表达很低,可能无法成为骨肉瘤的临床治疗靶点。
Objective To detect the expression of human telomerase reverse transcriptase (hTERT) in osteosarcoma and to investigate the expression of hTERT in osteosarcoma and its significance. Methods The expression of hTERT in human cervical cancer cell line HeLa, human osteosarcoma cell lines U2-OS, MG-63, SAOS-2 and 15 cases of osteosarcoma were detected qualitatively by immunocytochemistry / histochemical method. Western-blot, WB) quantitative detection of hTERT expression in the above cell lines and 7 cases of osteosarcoma. Results Immunocytochemistry showed that the expression of hTERT was the highest in HeLa cells (95.16%). The positive rates of hTERT in MG-63, SAOS-2 and U2-OS cell lines were 8.75%, 5.26% and 2.33% The positive rate of hTERT expression in 26.7% (4/15). Western blotting showed hTERT expression in Hela, MG-63 and two osteosarcoma samples (OS1 and OS2), with little hTERT expression in U2-OS and SAOS-2. Conclusion The expression of hTERT in osteosarcoma is very low and may not be the target of clinical treatment of osteosarcoma.